Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
Go back to Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis| Regeneron (NASDAQ: REGN) | Delayed: 618.03 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $618.03 | 52 Week High | $592.36 | |||
| Open | $618.03 | 52 Week Low | $325.35 | |||
| Day High | $618.03 | P/E | 162.21 | |||
| Day Low | $618.03 | EPS | $3.81 | |||
| Volume | 42 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 41.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.60 | 52 Week High | $44.76 | |||
| Open | $41.60 | 52 Week Low | $36.81 | |||
| Day High | $41.60 | P/E | N/A | |||
| Day Low | $41.60 | EPS | $0.00 | |||
| Volume | 1,676 | |||||
